BioNTech vs Viatris

BioNTech (BNTX), health care, and Viatris (VTRS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Viatris is worth $23.4B on the stock market and BioNTech $21B: Viatris is valued at 11% more. BioNTech's operating margin in its latest fiscal year was -49.0% and Viatris's -18.6%. Over the past year BioNTech's share price has moved -16.8% and Viatris's +93.7%.

Key facts

BioNTech market value
$21B
Viatris market value
$23.4B
BioNTech revenue
$3.2BFY to 2025-12-31
Viatris revenue
$14.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

BioNTech vs Viatris: every measure side by side
Measure BioNTech Viatris
SectorHealth CareHealth Care
Country Germany United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$21Blower$23.4Bhigher
Revenue$3.2Blower$14.3Bhigher
Earnings-$1.3Bhigher-$3.5Blower
Employees7,807lower30,000higher
Total assets$24.4Blower$37.2Bhigher
Valuation
P/E——
P/S6.6higher1.6lower
P/B—1.7
Dividend yield—2.31%
Profitability
Operating margin-49.0%lower-18.6%higher
Balance sheet
Net assets$21.3Bhigher$14.7Blower
Total liabilities$3.1Blower$22.5Bhigher
Total debt—$14.4B
Cash on hand$8.5Bhigher$1.3Blower
Price change
Today-0.47%higher-1.40%lower
1 year-16.8%lower+93.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns BNTX · Who owns VTRS

Further comparisons

Learn

Questions and answers

Which is bigger, BioNTech or Viatris?

By market value, Viatris is the larger: $23.4B against $21B for BioNTech. By revenue in its latest fiscal year, Viatris is the larger: $14.3B against $3.2B for BioNTech.

Which has the higher operating margin?

Viatris: -18.6%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both BioNTech and Viatris?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold BioNTech and 9 hold Viatris.

Cite this page

Funkfolio, “BioNTech vs Viatris”, data as of 18 November 2026. https://funkfolio.com/compare/bntx-vs-vtrs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.